Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 12, 2016 07:30 ET | Source: Amicus Therapeutics, Inc

Amicus Therapeutics Appoints Former FDA Division Deputy Director Andrew Mulberg as Vice President, Regulatory Strategy

Former Deputy Director of FDA Division of Gastroenterology and Inborn Errors Products Brings Significant Drug Development and Pharmaceutical Industry Experience CRANBURY,...
July 06, 2016 16:01 ET | Source: Amicus Therapeutics, Inc

Amicus Therapeutics Expands Biologics Pipeline with New Preclinical Program for Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency

CRANBURY, N.J., July 06, 2016 (GLOBE NEWSWIRE) -- Amicus Therapeutics, Inc. (Nasdaq:FOLD), a biotechnology company at the forefront of rare and orphan diseases, has expanded its biologics pipeline...
June 10, 2016 07:30 ET | Source: Amicus Therapeutics, Inc

Amicus Therapeutics Appoints Craig A. Wheeler to Board of Directors

CRANBURY, N.J., June 10, 2016 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a biotechnology company at the forefront of rare and orphan diseases, today announced the election and...
June 01, 2016 07:30 ET | Source: Amicus Therapeutics, Inc.

Amicus Therapeutics to Present at the Goldman Sachs 37th Annual Global Healthcare Conference

CRANBURY, N.J., June 01, 2016 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a biotechnology company at the forefront of therapies for rare and orphan diseases, today announced that John...
May 31, 2016 07:30 ET | Source: Amicus Therapeutics, Inc.

Amicus Therapeutics Announces European Commission Approval for Galafold™ (Migalastat) in Patients with Fabry Disease in European Union

Launch has Begun in Germany Broad Label for All Fabry Patients with an Amenable Genetic Mutation First Precision Medicine Approved for Fabry Disease CRANBURY, N.J., May 31, 2016 (GLOBE...
May 05, 2016 07:30 ET | Source: Amicus Therapeutics, Inc.

Amicus Therapeutics to Present at the Bank of America Merrill Lynch 2016 Health Care Conference

CRANBURY, N.J., May 05, 2016 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a biotechnology company at the forefront of therapies for rare and orphan diseases, today announced that Chip...
May 03, 2016 07:00 ET | Source: Amicus Therapeutics, Inc.

Amicus Therapeutics Announces First Quarter 2016 Financial Results and Corporate Updates

Positive CHMP Opinion for Broad Label of Migalastat for Fabry Disease in Patients with Amenable Mutations Actively Enrolling Patients Across Multiple Sites in Clinical Study to Investigate...
April 26, 2016 07:30 ET | Source: Amicus Therapeutics, Inc.

Amicus Therapeutics to Announce First Quarter 2016 Financial Results on May 3, 2016

CRANBURY, N.J., April 26, 2016 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a biotechnology company at the forefront of rare and orphan diseases, today announced a conference call and...
April 01, 2016 11:43 ET | Source: Amicus Therapeutics, Inc.

Amicus Therapeutics Receives Positive CHMP Opinion for Approval of Migalastat in Patients with Fabry Disease in European Union

Broad Label for All Fabry Patients with an Amenable Genetic Mutation Conference Call Today at 12:30 pm ET CRANBURY, N.J., April 01, 2016 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a...
March 22, 2016 07:30 ET | Source: Amicus Therapeutics, Inc.

Amicus Therapeutics Announces Expanded Access Program for Migalastat

CRANBURY, N.J., March 22, 2016 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a biotechnology company at the forefront of therapies for rare and orphan diseases, has initiated a reimbursed...